top of page
SABINA
OFFICIAL TITLE: PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN
PIK3CA/PTEN
altered
metaplastic
breast cancer
II
28
8
Spain
Recruitment
CLINICAL TRIAL DETAILS
THE PRIMARY OBJECTIVE FOR COHORT A IS TO ASSESS THE EFFICACY OF THE COMBINATION OF MEN1611 WITH ERIBULIN AS DETERMINED BY CLINICAL BENEFIT RATE IN UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HR-KNOWN/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED METAPLASTIC BREAST CARCINOMA. THE PRIMARY OBJECTIVE FOR COHORT B IS TO ASSESS THE EFFICACY OF MEN1611 AS MONOTHERAPY AS DETERMINED BY THE OBJECTIVE RESPONSE RATE AT 6 WEEKS.
SABINA AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
TRIAL RESUME
SABINA SITES
SPAIN
Instituto Valenciano de Oncología
SPAIN
Hospital Universitario Virgen del Rocío
SPAIN
Onkologikoa
SPAIN
Hospital Universitario de Torrejón
SPAIN
Hospital Universitario Clínico San Cecilio de Granada
SPAIN
Institut Català d’ Oncologia L’Hospitalet
SPAIN
Hospital Universitario de Torrejón
SPAIN
Hospital Universitari Vall D'Hebron
bottom of page